ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1324

Rheumatoid Arthritis Associated Interstitial Lung Disease – Patient Perceptions and Recommendations

Shirish Dubey1, Abhinav Peddasomayajula2, Damodar Makkuni3, Anupama Nandagudi4, Win Win Maw5 and Gouri M Koduri6, 1Oxford University Hospitals NHS FT, Oxford, United Kingdom, 2Mid and South Essex NHS Foundation Trust, Southend, England, United Kingdom, 3James Paget University Hospital NSH FT, Great Yarmouth, United Kingdom, 4MSEFT, Basildon, United Kingdom, 5Mid and South Essex NHS Foundation Trust, Chelmsford, England, United Kingdom, 6Southend Univeristy Hospitals NHS Trust, Essex, United Kingdom

Meeting: ACR Convergence 2024

Keywords: Access to care, Health Services Research, interstitial lung disease, Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Interstitial lung disease (ILD) is one of the complications of rheumatoid arthritis (RA) and has significant impact on morbidity and mortality. RA significantly reduces quality of life (QoL) and having ILD additionally further impacts their QoL. There are no studies on patient perceptions in RA-ILD and their needs. Understanding of patients’ level of knowledge and needs would help clinicians to develop integrated care service for these patients. This study aimed to shed light on patient perspectives, awareness, and impact on their life.

Methods: This is a prospective questionnaire study. There are no validated questionnaires, so we developed one based on Commissioning for Quality in RA Reported Experience Measure (CQRA-PREM) to assess patient understanding, experience, care co-ordination and impact of ILD on quality of life. This study was conducted at 5 sites following ethics approval. Subjects with RA-ILD were identified from routine clinics and database. Data was analysed using Microsoft Excel.

Results: Of the 64 responses, 58 were included for analysis. Table 1 describes the cohort characteristics and changes in treatment following diagnosis of ILD. 46 (79%) had ILD duration of less than 5 years.

Awareness of ILD:   37 (64%) responders said, they did not receive any or minimal information on ILD, whilst 10 (17%) received detailed information. 45(77%) were not provided any information on websites or patient organisations.

Treatment changes following diagnosis of ILD: Treatment changes following diagnosis of ILD were made for 30 (52%) subjects whilst in 28 (48%) subjects, no changes were made (see Table 1 for details)

Care Coordination:  29 (50%) subjects were attending respiratory clinics annually or more frequently with 22 (40%) at random intervals or infrequently. 26 (45%) had 6 to 12 monthly PFTs, 28 (48%) at random intervals and 2 never had any PFTs. Only 13 (22%) subjects felt involved with decisions involving their care, 43 (74%) did not.

Impact on Quality of Life: 31 (53%) stated that ILD affected their life as much as RA and 35 (60%) needed help from family members or carers. 31 (53%) managed to undertake low intensity exercise and 10 (17%) were able to do moderate exercise. Only 8 (14%) had received advice on chest physiotherapy.

Education and Self-Care:  Only 13 (22%) subjects were provided information on self-management program and 26 (45%) had departmental contact for queries.

Patient recommendations for service optimisation: Subjects preferred more information on ILD, frequent appointments with a specialist, early referral to specialist centre and better communication between specialists -see Figure 1. 18 (31%) subjects stated that they did not have enough knowledge to make recommendations.

Conclusion: RA-ILD has significant effect on Quality of life. This survey emphasized the need for better education to aid patient’s awareness and understanding of ILD. Early referral and better communication between specialists are needed to optimize the care for ILD patients.

Supporting image 1

Table 1: Demographics and cohort characteristics

Supporting image 2

Figure 1: Recommendations by the Patients


Disclosures: S. Dubey: Boehringer-Ingelheim, 1, Bristol-Myers Squibb(BMS), 1; A. Peddasomayajula: None; D. Makkuni: None; A. Nandagudi: None; W. Maw: None; G. Koduri: None.

To cite this abstract in AMA style:

Dubey S, Peddasomayajula A, Makkuni D, Nandagudi A, Maw W, Koduri G. Rheumatoid Arthritis Associated Interstitial Lung Disease – Patient Perceptions and Recommendations [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/rheumatoid-arthritis-associated-interstitial-lung-disease-patient-perceptions-and-recommendations/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatoid-arthritis-associated-interstitial-lung-disease-patient-perceptions-and-recommendations/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology